BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25815144)

  • 1. Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Yoneyama T; Ito S; Toda N
    ACS Med Chem Lett; 2015 Mar; 6(3):266-70. PubMed ID: 25815144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Kimura T; Toda N
    Bioorg Med Chem; 2015 Sep; 23(17):5546-65. PubMed ID: 26234904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.
    Negoro N; Sasaki S; Mikami S; Ito M; Suzuki M; Tsujihata Y; Ito R; Harada A; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Kogame A; Matsunaga S; Yasuma T; Momose Y
    ACS Med Chem Lett; 2010 Sep; 1(6):290-4. PubMed ID: 24900210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
    Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
    Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
    J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes.
    Toda N; Hao X; Ogawa Y; Oda K; Yu M; Fu Z; Chen Y; Kim Y; Lizarzaburu M; Lively S; Lawlis S; Murakoshi M; Nara F; Watanabe N; Reagan JD; Tian H; Fu A; Motani A; Liu Q; Lin YJ; Zhuang R; Xiong Y; Fan P; Medina J; Li L; Izumi M; Okuyama R; Shibuya S
    ACS Med Chem Lett; 2013 Aug; 4(8):790-4. PubMed ID: 24900747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of an Orally Efficacious GPR40/FFAR1 Receptor Agonist.
    Agarwal S; Sasane S; Deshmukh P; Rami B; Bandyopadhyay D; Giri P; Giri S; Jain M; Desai RC
    ACS Med Chem Lett; 2016 Dec; 7(12):1134-1138. PubMed ID: 27994752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
    Brown SP; Dransfield PJ; Vimolratana M; Jiao X; Zhu L; Pattaropong V; Sun Y; Liu J; Luo J; Zhang J; Wong S; Zhuang R; Guo Q; Li F; Medina JC; Swaminath G; Lin DC; Houze JB
    ACS Med Chem Lett; 2012 Sep; 3(9):726-30. PubMed ID: 24900539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
    Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
    J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel free fatty acid receptor 1 (GPR40/FFAR1) agonist, MR1704, enhances glucose-dependent insulin secretion and improves glucose homeostasis in rats.
    Tsuda N; Kawaji A; Sato T; Takagi M; Higashi C; Kato Y; Ogawa K; Naba H; Ohkouchi M; Nakamura M; Hosaka Y; Sakaki J
    Pharmacol Res Perspect; 2017 Aug; 5(4):. PubMed ID: 28805970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat.
    Doshi LS; Brahma MK; Sayyed SG; Dixit AV; Chandak PG; Pamidiboina V; Motiwala HF; Sharma SD; Nemmani KV
    Metabolism; 2009 Mar; 58(3):333-43. PubMed ID: 19217448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of AM-6226: A Potent and Orally Bioavailable GPR40 Full Agonist That Displays Efficacy in Nonhuman Primates.
    Brown SP; Dransfield P; Vimolratana M; Zhu L; Luo J; Zhang J; Jiao X; Pattaropong V; Wong S; Zhuang R; Swaminath G; Houze JB; Lin DC
    ACS Med Chem Lett; 2018 Jul; 9(7):757-760. PubMed ID: 30034614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMG 837: a potent, orally bioavailable GPR40 agonist.
    Houze JB; Zhu L; Sun Y; Akerman M; Qiu W; Zhang AJ; Sharma R; Schmitt M; Wang Y; Liu J; Liu J; Medina JC; Reagan JD; Luo J; Tonn G; Zhang J; Lu JY; Chen M; Lopez E; Nguyen K; Yang L; Tang L; Tian H; Shuttleworth SJ; Lin DC
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1267-70. PubMed ID: 22217876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists.
    Negoro N; Sasaki S; Ito M; Kitamura S; Tsujihata Y; Ito R; Suzuki M; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Yasuma T; Momose Y
    J Med Chem; 2012 Feb; 55(4):1538-52. PubMed ID: 22242551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion.
    Tanaka H; Yoshida S; Oshima H; Minoura H; Negoro K; Yamazaki T; Sakuda S; Iwasaki F; Matsui T; Shibasaki M
    J Pharmacol Exp Ther; 2013 Sep; 346(3):443-52. PubMed ID: 23853170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and optimization of 2,3-dihydrobenzo[b][1,4]dioxine propanoic acids as novel GPR40 agonists with improved pharmacokinetic and safety profiles.
    Guo B; Guo S; Huang J; Li J; Li J; Chen Q; Zhou X; Xie X; Yang Y
    Bioorg Med Chem; 2018 Dec; 26(22):5780-5791. PubMed ID: 30392954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
    Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
    J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of orally effective and safe GPR40 agonists by incorporating a chiral, rigid and polar sulfoxide into β-position to the carboxylic acid.
    Chen C; Guo SM; Sun Y; Li H; Hu N; Yao K; Ni H; Xia Z; Xu B; Xie X; Long YQ
    Eur J Med Chem; 2023 May; 251():115267. PubMed ID: 36933395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.